Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 186
Filter
1.
Nurs Stand ; 39(2): 39-44, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38044818

ABSTRACT

Cellulitis is an acute bacterial infection that affects the deep dermis and surrounding subcutaneous tissue. Although it is a common condition, it is often misdiagnosed because it can mimic a range of conditions that also cause inflamed, red, irritated and painful skin. Such misdiagnoses may lead to unnecessary hospital admissions and antibiotic overuse, with most alternative diagnoses being non-infectious. Undertaking a holistic patient assessment, skin assessment and thorough clinical history is important in the diagnosis of cellulitis, and it is vital to use a collaborative multidisciplinary approach in its acute management and to prevent recurrence. This article defines the term cellulitis and explores its presenting features. The author also discusses the associated risk factors, clinical assessment techniques and effective management strategies, as well as outlining the actions that nurses can take to prevent recurrence.


Subject(s)
Anti-Bacterial Agents , Cellulitis , Humans , Cellulitis/diagnosis , Cellulitis/therapy , Cellulitis/chemically induced , Anti-Bacterial Agents/therapeutic use , Hospitalization , Diagnostic Errors/prevention & control , Diagnosis, Differential
3.
J Oncol Pharm Pract ; 29(7): 1789-1792, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37401244

ABSTRACT

INTRODUCTION: Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and soft tissue reactions. CASE REPORT: We report two cases of EV extravasation with subsequent development of bullae and cellulitis. MANAGEMENT AND OUTCOME: They were both treated for cellulitis and had conservative management without surgical intervention and were able to resume treatment with Enfortumab vedotin without subsequent adverse events. DISCUSSION: We propose that EV acts as a vesicant upon extravasation, highlight measures to prevent extravasation events, and encourage appropriate measures when dealing such as attempt of aspiration, removal of catheter, application of compresses, and thorough documentation with photographic evidence.


Subject(s)
Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Humans , Carcinoma, Transitional Cell/drug therapy , Urinary Bladder Neoplasms/drug therapy , Cellulitis/chemically induced , Antibodies, Monoclonal/adverse effects
4.
Anticancer Drugs ; 34(1): 187-189, 2023 01 01.
Article in English | MEDLINE | ID: mdl-36539371

ABSTRACT

EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report a case of severe cutaneous toxicity secondary to cetuximab associated with bacterial cellulitis. A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients. Few days later, the patient becomes febrile, and the rash becomes more diffuse with a sandpaper appearance on the face, neck, chest, and flexor creases with exfoliation of large areas of skin. A bacterial cellulitis secondary to a dermatologic severe toxicity of Cetuximab was suspected. The patient started on antibiotics and local treatment with good response. This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.


Subject(s)
Bacteremia , Colorectal Neoplasms , Drug Eruptions , Exanthema , Skin Diseases , Female , Humans , Middle Aged , Cetuximab/adverse effects , Antibodies, Monoclonal , Cellulitis/chemically induced , Cellulitis/drug therapy , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Drug Eruptions/prevention & control , Colorectal Neoplasms/pathology , Skin Diseases/chemically induced , Exanthema/chemically induced , Exanthema/drug therapy , ErbB Receptors , Bacteremia/chemically induced , Bacteremia/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fluorouracil/therapeutic use , Leucovorin/therapeutic use
5.
J Stomatol Oral Maxillofac Surg ; 124(2): 101334, 2023 04.
Article in English | MEDLINE | ID: mdl-36400392

ABSTRACT

OBJECTIVE: Nowadays, dermal filler injections in the face, are widespread. However, late complications are rarely reported and misunderstood. Moreover, they could be potentially severe, particularly cellulitis which is life-threatening. Reactivation of the biofilm and the hypersensitivity reaction are the main etiopathogenic factors of such unpredictable infections and granuloma reactions. Through four cases of foreign-body cellulitis, this article aims to explain the causality of filler material, and trigger conditions while emphasizes the prompt and adequate solution. MATERIAL AND METHODS: This work is a retrospective study and chart review which was granted an exemption by the author's institutional review board (IRB). Four women ranging from 27 to 55 years old, presented with onset symptoms of cellulitis of the face and inflammatory swelling of the lip. The hyaluronic acid filler was injected a long date prior. Trigger conditions caused the hatching of such complications which were solved with medical treatment without any filler dissolution or removal. RESULTS: Improvement of the symptoms was remarkable within the three and fifth days of antibiotic therapy. There was no abscess formation or, recurrence for more than one-year follow-up. CONCLUSION: The screening for dermal filler deposits must be considered for any inflammatory reaction of the face. Their causality should be discussed as well as the infectious and/or immunologic etiology, ensuring prompt and adequate medical treatment. Thus abscess formation could then not happen, and the resolution of the inflammatory reaction will be obtained. The extraction of filler material or the use of hyaluronidase should not be mandatory and will be done on a case-by-case basis.


Subject(s)
Communicable Diseases , Dermal Fillers , Foreign Bodies , Female , Humans , Adult , Middle Aged , Dermal Fillers/adverse effects , Cellulitis/chemically induced , Cellulitis/diagnosis , Retrospective Studies
6.
Lancet Neurol ; 21(12): 1099-1109, 2022 12.
Article in English | MEDLINE | ID: mdl-36402160

ABSTRACT

BACKGROUND: Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation of levodopa and carbidopa prodrugs that is delivered as a 24-h/day continuous subcutaneous infusion, and we aimed to assess the safety and efficacy of this formulation in patients with advanced Parkinson's disease. METHODS: A 12-week randomised, double-blind, double-dummy, active-controlled study was done at 65 academic and community study centres in the USA and Australia. Patients with levodopa-responsive advanced Parkinson's disease inadequately controlled on current therapy, including at least 2·5 h of average daily off time, were randomly assigned (1:1) to continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo or to oral immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution. Randomisation was stratified by site by means of a permutated-block schedule with a block size of two. The participants, treating investigators, study site personnel, and sponsor were masked to treatment group allocation. The primary and first key secondary endpoint in the hierarchical testing strategy were change from baseline to week 12 in on time without troublesome dyskinesia and off time, respectively; both endpoints were evaluated by an intention-to-treat analysis applying a mixed model for repeated measures analysis. Safety and tolerability were assessed throughout the study. The study is completed and is listed on ClinicalTrials.gov, NCT04380142. FINDINGS: Between Oct 19, 2020, and Sept 29, 2021, of 270 participants screened and 174 enrolled, 141 were randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n=74) or oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67). Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (-2·75 [0·50] vs -0·96 [0·49] h; difference -1·79 h, -3·03 to -0·54; p=0·0054). Hierarchical testing ended after the first secondary endpoint. Adverse events were reported in 63 (85%) of 74 patients in the foslevodopa-foscarbidopa group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse events were similar between the groups (six [8%] of 74 vs four [6%] of 67, respectively). The most frequent adverse events in the foslevodopa-foscarbidopa group were infusion site adverse events (erythema 20 [27%]), pain 19 [26%]), cellulitis (14 [19%]), and oedema (nine [12%]), most of which were non-serious and mild-moderate in severity. The only system organ class that had more than one serious adverse event in the foslevodopa-foscarbidopa group was infections and infestations (catheter site cellulitis [one [1%]] and infusion site cellulitis [one [1%]). Adverse events led to premature discontinuation of study drug in 16 (22%) of 74 participants in the foslevodopa-foscarbidopa group versus one (1%) of 67 participants in the oral levodopa-carbidopa group. INTERPRETATION: Foslevodopa-foscarbidopa improved motor fluctuations, with benefits in both on time without troublesome dyskinesia and off time. Foslevodopa-foscarbidopa has a favourable benefit-risk profile and represents a potential non-surgical alternative for patients with advanced Parkinson's disease. FUNDING: AbbVie.


Subject(s)
Dyskinesias , Parkinson Disease , Humans , Carbidopa/adverse effects , Levodopa/adverse effects , Antiparkinson Agents/adverse effects , Parkinson Disease/drug therapy , Cellulitis/chemically induced , Cellulitis/drug therapy , Dopamine Agonists , Dyskinesias/drug therapy
8.
Anticancer Drugs ; 32(10): 1127-1130, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34282744

ABSTRACT

Avapritinib is a tyrosine kinase inhibitor currently being investigated on clinical trials for the treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST). It has been recently approved by the Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic GIST harbouring PDGFRa Exon 18 mutation and by the European Medicines Agency for the treatments of unresectable or metastatic GIST harbouring the PDGFRa D842V mutation. We report a clinical case of a 76-year-old female, diagnosed with a stage IV GIST, treated with avapritinib 300 mg once daily. through compassionate use who experienced an intraocular side effect not previously reported avapritinib. She developed preseptal cellulitis on her right eye following 2 months of treatment with avapritinib and, subsequently evolved to an intraocular inflammatory reaction and persistent corneal epithelial defect. The treatment with avapritinib was stopped and the patient received corticosteroid and corneal regenerating agents. The symptoms resolved within 1 month and the patient has remained on stable disease at two subsequent adjusted avapritinib doses (100 mg once daily) for over 1 year.


Subject(s)
Antineoplastic Agents/adverse effects , Cellulitis/chemically induced , Eye Diseases/chemically induced , Inflammation/chemically induced , Pyrazoles/adverse effects , Pyrroles/adverse effects , Triazines/adverse effects , Aged , Antineoplastic Agents/therapeutic use , Epithelium, Corneal , Female , Gastrointestinal Stromal Tumors/drug therapy , Gastrointestinal Stromal Tumors/pathology , Humans , Neoplasm Metastasis , Neoplasm Staging , Pyrazoles/therapeutic use , Pyrroles/therapeutic use , Receptor, Platelet-Derived Growth Factor alpha/genetics , Triazines/therapeutic use
9.
J Prim Care Community Health ; 12: 21501327211024431, 2021.
Article in English | MEDLINE | ID: mdl-34120504

ABSTRACT

The term "COVID arm" has been coined to describe a harmless delayed hypersensitivity reaction occurring approximately a week after administration of the novel SARS-CoV-2 mRNA vaccine. It appears as a red, warm, pruritic, indurated, or swollen area in the vicinity of the vaccine site. These reactions, especially if accompanied by systemic symptoms, have been mistaken for cellulitis. We report 3 cases of COVID arm, 2 of which were mistaken for cellulitis. Distinguishing features of COVID arm from cellulitis include pruritus as a common finding, occurrence approximately a week after vaccination, a lack of progression of symptoms, rapid response to topical steroids, and/or spontaneous resolution usually over 4 to 5 days.Practice Points:• Patients receiving SARS-CoV-2 vaccines may experience delayed hypersensitivity reactions characterized by erythema, swelling, and itching occurring near the vaccination site (COVID arm), approximately a week after vaccination.• Clinicians can distinguish SARS-CoV-2 vaccine reactions from cellulitis by the time of onset (approximately a week vs 5 days), by the lack of progression of symptoms, and resolution over 4 to 5 days.• Severe cases of COVID arm may be treated with topical steroids.


Subject(s)
COVID-19 , Hypersensitivity, Delayed , Vaccines , Arm , COVID-19 Vaccines , Cellulitis/chemically induced , Cellulitis/diagnosis , Diagnostic Errors , Humans , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/diagnosis , SARS-CoV-2
10.
Dermatol Surg ; 47(1): 80-85, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33347003

ABSTRACT

BACKGROUND: VYC-20L is a hyaluronic acid soft tissue filler with lidocaine designed to restore facial volume. OBJECTIVE: Evaluate the safety and effectiveness of VYC-20L in patients with chin retrusion. MATERIALS AND METHODS: Adults with chin retrusion were randomized (3:1) to receive VYC-20L in the chin at study onset (treatment group) or 6 months later (control group). The primary effectiveness end point was ≥1-point improvement on the Allergan Chin Retrusion Scale (ACRS) from baseline at Month 6. Safety assessments included injection site responses (ISRs) and adverse events (AEs). RESULTS: VYC-20L was administered to 192 participants (treatment group, n = 144; control group, n = 48). At Month 6, significantly more participants had an ACRS response in the treatment versus control group (56.3% vs 27.5%; p = .0019). Effectiveness was also demonstrated by the proportion of participants with improved/much improved Global Aesthetic Improvement Scale scores and responses on the FACE-Q Satisfaction with Chin questionnaire and FACE-Q Psychological Wellbeing module. Treatment benefit remained evident at Month 12. Most common ISRs were tenderness (81.1%) and firmness (75.1%). One participant (0.5%) discontinued the study due to 2 treatment-related serious AEs of facial cellulitis and injection site inflammation, both resolved without sequelae. CONCLUSION: VYC-20L significantly improved an ACRS response and was generally safe and well tolerated.


Subject(s)
Chin , Cosmetic Techniques , Dermal Fillers/administration & dosage , Hyaluronic Acid/administration & dosage , Adult , Aged , Aged, 80 and over , Cellulitis/chemically induced , Dermal Fillers/adverse effects , Esthetics , Female , Gels , Humans , Hyaluronic Acid/adverse effects , Injection Site Reaction , Male , Middle Aged , United States
14.
Clin Exp Nephrol ; 24(9): 779-788, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32342290

ABSTRACT

OBJECTIVE: Skin and soft tissue infection (SSTI) is the most common of infectious diseases with high morbidity and mortality. However, the clinical characteristics of SSTI in patients with nephrotic syndrome (NS), especially in those patients who received immunosuppressive therapy, are still lacking. The present study was conducted to investigate the clinical characteristics and outcomes of SSTI in patients with NS. METHODS: A retrospective study was carried out among the patients diagnosed with NS and SSTI, who have priorly received or currently have been receiving immunosuppressive therapy between April 2011 and January 2019; the clinical profile included patient's baseline characteristics, clinical presentation, microbiological findings, treatment, and prognosis. RESULTS: A total of 70 patients were analyzed. Results showed that more than half of the patients were under 35 years old, and moderate infection was the most common type of SSTI. Leg and cellulitis were the most common site of lesion and the typical clinical manifestation of SSTI, respectively. Patients in the severe infection group have a higher level of procalcitonin (PCT) and C-reactive protein (CRP), while a lower level of albumin, CD4+ T and CD8+ T cell count. Moreover, the gram-negative bacteria were the primary pathogens of SSTI in patients with NS, and Klebsiella pneumoniae were the most frequent strains isolated from those patients. Besides, patients in the mild and moderate infection groups experienced a better outcome. CONCLUSIONS: Patients with NS and SSTI usually showed a satisfying outcome with proper anti-infection treatment, but severe SSTI can be life-threatening.


Subject(s)
Cellulitis/chemically induced , Immunosuppressive Agents/adverse effects , Nephrotic Syndrome/drug therapy , Soft Tissue Infections/chemically induced , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , C-Reactive Protein/metabolism , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes , Cellulitis/blood , Cellulitis/drug therapy , Cellulitis/microbiology , Child , Cyclophosphamide/adverse effects , Female , Humans , Immunosuppression Therapy/adverse effects , Leg , Male , Middle Aged , Prednisone/adverse effects , Procalcitonin/blood , Retrospective Studies , Serum Albumin/metabolism , Severity of Illness Index , Soft Tissue Infections/blood , Soft Tissue Infections/drug therapy , Soft Tissue Infections/microbiology , Tacrolimus/adverse effects , Young Adult
15.
Blood ; 136(1): 71-80, 2020 07 02.
Article in English | MEDLINE | ID: mdl-32244252

ABSTRACT

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amyloidosis. We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. CyBorD was given weekly for 6 cycles. Patients had a median of 2 involved organs (kidney, 68%; cardiac, 61%). Patients received a median of 16 (range, 1-23) treatment cycles. Treatment-emergent adverse events were consistent with DARA SC in MM and CyBorD. Infusion-related reactions occurred in 1 patient (grade 1). No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplant. Overall hematologic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at 1, 3, and 6 months, respectively. Renal response occurred in 6 of 16, 7 of 15, and 10 of 15 patients, and cardiac response occurred in 6 of 16, 6 of 13, and 8 of 13 patients at 3, 6, and 12 months, respectively. Hepatic response occurred in 2 of 3 patients at 12 months. Daratumumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematologic and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT03201965.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunoglobulin Light-chain Amyloidosis/drug therapy , Acute Kidney Injury/chemically induced , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bortezomib/administration & dosage , Bortezomib/adverse effects , Cellulitis/chemically induced , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Female , Follow-Up Studies , Humans , Immunoglobulin Heavy Chains/blood , Immunoglobulin Light Chains/blood , Immunoglobulin Light-chain Amyloidosis/blood , Immunoglobulin Light-chain Amyloidosis/pathology , Immunoglobulin Light-chain Amyloidosis/urine , Male , Middle Aged , Nervous System/pathology , Pneumonia/chemically induced , Treatment Outcome , Viscera/pathology
16.
Dermatol Online J ; 26(2)2020 Feb 15.
Article in English | MEDLINE | ID: mdl-32239887

ABSTRACT

Follicular occlusion triad is a symptom complex of three conditions with a similar pathophysiology including hidradenitis suppurativa (HS), dissecting cellulitis of the scalp, and acne conglobata. Although the exact pathogenesis of the triad is unknown, it appears to be related to follicular occlusion in areas with apocrine glands. Wolf isotopic response refers to the occurrence of a new dermatosis at the site of another, unrelated, previously healed dermatosis. We present a 26-year-old man with a history of pemphigus foliaceus (PF) who developed large draining nodules with scarring and sinus tracts, compatible with follicular occlusion triad, preferentially at areas previously affected by PF thirteen months after treatment with rituximab. To the authors' knowledge there are no reported cases of follicular occlusion triad or HS manifesting as an isotopic response. However, one member of the triad, HS, has been reported to occur infrequently following the use of biologic agents such as adalimumab, infliximab, tocilizumab, and rituximab for chronic immune-mediated inflammatory diseases (psoriasis, Crohn disease, rheumatoid arthritis, and ankylosing spondylitis).


Subject(s)
Acne Conglobata/chemically induced , Cellulitis/chemically induced , Hidradenitis Suppurativa/chemically induced , Immunologic Factors/adverse effects , Rituximab/adverse effects , Acne Conglobata/pathology , Acne Vulgaris/drug therapy , Adult , Anti-Bacterial Agents/adverse effects , Cellulitis/pathology , Doxycycline/adverse effects , Hidradenitis Suppurativa/pathology , Humans , Male , Pemphigus , Skin/pathology
18.
J Oncol Pharm Pract ; 26(2): 487-491, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31216242

ABSTRACT

INTRODUCTION: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ibrutinib. The mechanism in which ibrutinib can cause skin toxicities has been thought due to the inhibition of epidermal growth factor; c-Kit and platelet-derived growth factor receptor). Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy. CASE REPORT: A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420 mg orally daily following multiple lines of therapy. Three months following ibrutinib, the patient developed multiple hyper pigmented lesions over both forearms then over both thighs; buttocks and lower limbs. The lesions were labeled as ecthyma and cellulitis that started as papules, which progressed to pustules. MANAGEMENT AND OUTCOMES: The patient required admission in which he received prolonged course of antibiotics. Biopsy from the wound showed soft tissue fragment infiltrated by acute and chronic inflammatory cells with necrosis; rare foreign body giant cells and granulation tissue formation; suggestive of abscess. Subsequently, ibrutinib was stopped permanently. DISCUSSION: This is the first case description of an ibrutinib-associated sever skin toxicity in Qatar. The provided information regarding the clinical descriptions of toxicity profiles in general and skin-based in particular is valuable information for daily clinical practice, especially when selecting the optimum first-line treatment for the patient.


Subject(s)
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Cellulitis/chemically induced , Ecthyma/chemically induced , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Neoplasm Recurrence, Local/drug therapy , Pyrazoles/adverse effects , Pyrimidines/adverse effects , Adenine/analogs & derivatives , Aged , Cellulitis/diagnosis , Ecthyma/diagnosis , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Male , Neoplasm Recurrence, Local/diagnosis , Piperidines , Protein Kinase Inhibitors/therapeutic use , Skin/drug effects , Skin/pathology
19.
Curr Oncol ; 26(5): e703-e706, 2019 10.
Article in English | MEDLINE | ID: mdl-31708665

ABSTRACT

Gemcitabine is a chemotherapeutic agent used in a wide variety of solid tumours. Known side effects include a dose-limiting myelosuppressive toxicity, mild rash, and radiation-dependent dermatitis. Rarely, localized inflammation in the form of pseudocellulitis has also been observed. We present the case of a 77-year-old woman with a history of a Whipple procedure for pancreatic adenocarcinoma who presented to the emergency department after the start of gemcitabine therapy with increased erythema, swelling, and tenderness in her lower legs. Relevant past medical history included peripheral vascular disease, dyslipidemia, and hypertension. A diagnosis of gemcitabine-induced pseudocellulitis aggravated by venous stasis was confirmed after an extensive workup. This case report and the literature review describe this rare reaction, highlighting the need for increased recognition to avoid unnecessary therapeutic intervention.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Cellulitis/chemically induced , Deoxycytidine/analogs & derivatives , Adenocarcinoma/drug therapy , Aged , Deoxycytidine/adverse effects , Female , Humans , Pancreatic Neoplasms/drug therapy , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL
...